Center For Sight offers breakthrough treatment for patients with Age-related Macular Degeneration – SYFOVRE™ (PEGCETACOPLAN INJECTION)
Patients at Center For Sight, a multispecialty ophthalmology practice which operates 18 eye clinics and two surgery centers in Florida, is among the first in the nation to have access to SYFOVRE™, a new drug from Apellis Pharmaceuticals, that can slow the progression of retina damage caused by Dry Age-related Macular Degeneration (Dry AMD).
Dry AMD is an eye condition in which deterioration of the retina is associated with cell loss called geographic atrophy and/or yellow deposits called drusen that develop under the retina in the portion of the retina responsible for central vision called the macula. This leads to damage to photoreceptors in the eye and disrupts their ability to process light and turn it into the image we see.
Clinical trials found the drug treatment, an intravitreal dose of SYFOVRE™ (pegcetacoplan) manufactured by Apellis Pharmaceuticals, could curtail geographic atrophy, an advanced form of Dry Age-related Macular Degeneration that can lead to central vision loss.
“Center For Sight physicians are dedicated to offering the most advanced and effective treatment options to our patients to help enhance their quality of life, no matter their diagnosis,” said Dr. Tanuj Banker, retina surgeon at Center For Sight. “The approval and availability of this new treatment brings hope to patients with Dry AMD, and we are encouraged and pleased to offer this new treatment to qualifying patients.”
Prior to Apellis developing its new medication, the most common treatment for patients with geographic atrophy as part of Dry AMD was a vitamin regimen. For those that have Dry AMD with geographic atrophy it is important to discuss with your doctor this new treatment before vision is lost.
To learn more about treatment for AMD, call Center For Sight at (941) 925-2020 or request an appointment online.
